{
    "organizations": [],
    "uuid": "9b95c0bbf264309857731a1aa0f48920b71e8666",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biohaven-says-achieved-both-co-pri/brief-biohaven-says-achieved-both-co-primary-regulatory-endpoints-in-two-pivotal-phase-3-trials-of-rimegepant-idUSASC09TJV",
    "ord_in_thread": 0,
    "title": "BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:\n* BIOHAVEN ANNOUNCES SUCCESSFUL ACHIEVEMENT OF BOTH CO-PRIMARY REGULATORY ENDPOINTS IN TWO PIVOTAL PHASE 3 TRIALS OF RIMEGEPANT AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE\n* RESULTS ARE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL ACROSS MULTIPLE OUTCOME MEASURES\n* EFFICACY AND SAFETY RESULTS WERE CONSISTENT ACROSS BOTH PHASE 3 TRIALS.\n* ON SCHEDULE TO SUBMIT AN NDA FOR RIMEGEPANT IN 2019â€‹ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-03-26T15:05:00.000+03:00",
    "crawled": "2018-03-27T12:11:07.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "biohaven",
        "pharmaceutical",
        "holding",
        "company",
        "ltd",
        "biohaven",
        "announces",
        "successful",
        "achievement",
        "regulatory",
        "endpoint",
        "two",
        "pivotal",
        "phase",
        "trial",
        "rimegepant",
        "oral",
        "cgrp",
        "receptor",
        "antagonist",
        "acute",
        "treatment",
        "migraine",
        "result",
        "statistically",
        "significant",
        "clinically",
        "meaningful",
        "across",
        "multiple",
        "outcome",
        "measure",
        "efficacy",
        "safety",
        "result",
        "consistent",
        "across",
        "phase",
        "trial",
        "schedule",
        "submit",
        "nda",
        "rimegepant",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}